Benzarone

Benzarone is an oral inhibitor of human urate transporter 1 (hURAT1) with an IC50 value of 2.8 μM, and it also acts as an uncoupler of oxidative phosphorylation. Benzarone can cause liver damage and promote cell apoptosis and necrosis. Benzarone can be used to lower serum uric acid levels and for research in vascular diseases[1][2][3].

Product Specifications

CAS Number

[1477-19-6]

UNSPSC

12352005

Hazard Statement

H302, H413

Target

Apoptosis; Oxidative Phosphorylation; URAT1

Type

Reference compound

Related Pathways

Apoptosis; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/benzarone.html

Purity

99.68

Solubility

DMSO : ≥ 100 mg/mL

Smiles

CCC1=C(C(C2=CC=C(O)C=C2)=O)C3=CC=CC=C3O1

Molecular Formula

C17H14O3

Molecular Weight

266.29

Precautions

H302, H413

References & Citations

[1]Wempe MF, et, al. Developing potent human uric acid transporter 1 (hURAT1) inhibitors. J Med Chem. 2011 Apr 28;54 (8) :2701-13. |[2]Priska Kaufmann, et al. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology. 2005 Apr;41 (4) :925-35.|[3]S G Wood, et al. Metabolic fate of the thrombolytic agent benzarone in man: comparison with the rat and dog.